Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback